Mounjaro price increase in the UK: Why patients are turning to Wegovy

We know sudden medication price rises can be stressful and disruptive, especially when you’ve built momentum with your weight loss journey.

From 1 September 2025, Eli Lilly, the manufacturer of Mounjaro (tirzepatide), will increase its UK list price to align with other developed countries [1]. This nationwide change applies to providers including pharmacies, private clinics, and digital platforms.

In response, we’ve lowered the price of our Wegovy programme by 25%, and we’re making it easier for patients to switch without starting over, so that effective treatment remains within reach for as many people as possible.

Quick summary: Mounjaro price increase UK 2025

Are Mounjaro prices increasing?

Yes. Eli Lilly, the manufacturer of Mounjaro, has confirmed a UK-wide list price increase starting 1 September 2025.

This affects every provider — pharmacies, private clinics and digital providers.

Why has Mounjaro gone up in price?

Eli Lilly has said the rise is intended to align UK Mounjaro pricing with global market levels.

When Mounjaro first launched here, the cost was intentionally set lower to accelerate patient access. Now, with more clinical data and a mature market, the manufacturer is revising its pricing upwards.

Because all providers purchase Mounjaro through wholesalers, these increases flow directly to patient pricing nationwide.

What does this mean for patients?

We understand this change may feel unsettling, especially if you’ve been seeing results and want to stay on track.

Here’s what it means for you — and how we’re helping:

• Nationwide impact: Every Mounjaro patient in the UK will be affected.
• Juniper’s commitment: We’re working to minimise the impact and will share confirmed pricing details soon.
• Proactive alternatives: We’re introducing a lower-priced Wegovy programme and a streamlined switching process for patients who want to keep their results on track while reducing costs.

Why Wegovy is now the go-to option

Wegovy (semaglutide) is now the more affordable choice for many — but cost isn’t the only reason:

• Comparable results: Higher-dose Wegovy (7.2mg) delivers an average weight loss of ~21% at 72 weeks, matching Mounjaro’s clinical outcomes [2]. If you’re searching for “Is Wegovy as effective as Mounjaro?”, the answer is increasingly yes with these new doses.
• Heart health benefits: Wegovy is the only GLP-1 in the UK licensed to reduce the risk of heart attack and stroke in people with obesity and heart disease [3].
• Better care = better results: Juniper patients can achieve up to 40% more weight loss after 16 weeks than clinical trial averages [4]— thanks to unlimited dose adjustments, pharmacist-led monitoring, and personalised coaching.

Compare Mounjaro and Wegovy side by side →

Can I start on a high dose when switching from Mounjaro to Wegovy?

Yes — if you switch from Mounjaro to Wegovy with Juniper’s clinical switching protocol, you may be eligible to start on an equivalent high dose immediately. This keeps your weight loss on track by avoiding treatment gaps, side effects from restarting at a low dose, and any loss of momentum.

With Juniper, you get:

• A high dose matched to your progress — tailored to your previous medication, dose tolerance, and results so far.
• Clinician-led safety — pharmacists and prescribers guide your transition for the best outcomes.
• Complete support — pharmacist check-ins, coaching, and plateau-busting guidance.

Switching doesn’t mean starting over — with Juniper, it’s safe, seamless, and designed to protect your results.

Start your Wegovy switch today →

How do prices of Mounjaro and Wegovy compare?

From 1 September 2025, Mounjaro prices will rise across all UK providers.

Juniper has responded by cutting Wegovy prices by 25% for a limited time. For most patients, Wegovy is now the more cost-effective option, with the same level of clinical care included.

^{*New members get a discount on their first order}

What makes Juniper’s programme different?

Clinical research shows that Juniper patients achieve up to 40% more weight loss after 16 weeks compared to average results in Wegovy clinical trials. [1]

This difference comes from how we combine the medication with ongoing expert care:

• Unlimited dose adjustments to match your needs and response.
• Clinical oversight with pharmacist and prescriber check-ins to ensure safety and effectiveness.
• Coaching focused on nutrition, exercise, and behaviour change.
• Plateau management strategies to keep results moving if progress slows.

By pairing effective medication with this level of medical and behavioural support, Juniper helps patients get the most from their treatment.

‍

Key Takeaway

Mounjaro remains an effective treatment, but with rising costs, many patients are switching to Wegovy — especially now that results are comparable.

At Juniper, we make that switch seamless and fully supported — so you can protect your progress without paying more than you need to.

Start your Wegovy switch today →

‍

FAQs

Is Wegovy as effective as Mounjaro?

Yes. At the new highest doses (up to 7.2mg weekly), Wegovy delivers an average ~21% weight loss at 72 weeks, which is comparable to Mounjaro in clinical studies.

Juniper patients often achieve even greater results thanks to our care model — which combines unlimited dose adjustments, pharmacist-led monitoring, and ongoing support to keep results moving.

‍

What’s the main difference between Wegovy and Mounjaro?

Both are once-weekly GLP-1 injections that work by reducing appetite and supporting weight loss. The key difference:

Wegovy contains semaglutide, a GLP-1 that’s been used by over 8 million people worldwide and studied in more than 39,000 clinical trial participants. Mounjaro contains tirzepatide.

‍

How does switching from Mounjaro to Wegovy work?

Juniper’s clinical switching protocol is designed to make the change simple and safe:

1. Review — Your clinician assesses your treatment history and dose tolerance.
2. Match — If eligible, you start on an equivalent high dose to avoid losing progress.
3. Transition — Only a 7-day window is required between your last Mounjaro dose and your first Wegovy dose (most providers require 28 days).
4. Support — Pharmacist check-ins, dose adjustments, and lifestyle guidance keep you on track.

‍

What if my BMI is now below the usual starting level?

If you’re already on GLP-1 treatment, you may still be eligible to switch even if your BMI is below the standard starting threshold. As long as your BMI is above 22 and you meet our clinical safety criteria, you’re likely to be approved.

‍

What evidence do I need to prove I’ve been on a GLP-1 before?

We accept multiple forms of proof, as long as they show:

• Medication name and strength
• Date of prescription, order, or dispensing
• Your name or email
• Name of the provider or pharmacy

Examples:

• Photo of the dispensing label on your medication box
• Email confirmation of your order or prescription from your provider

‍

Is it safe to switch mid-treatment?

Yes — switching between GLP-1 medications is considered safe under clinical supervision. Wegovy is often well tolerated and may even be a better fit for some patients, as it doesn’t interact with the contraceptive pill.

‍

What support does Juniper provide during a switch?

Our team manages the entire process, including:

• Matching you to an equivalent, higher starting dose if you’re switching from Mounjaro to Wegovy, or switching providers
• Regular pharmacist check-ins to monitor safety and results
• Dose adjustments as needed
• Guidance to manage plateaus and side effects

‍

How long does the switch take?

In most cases, switching can happen immediately. If a review is required, you’ll usually hear from your prescriber within one working day.

‍

Can I go back to Mounjaro if Wegovy isn’t right for me?

Yes. If Wegovy doesn’t work for you, your Juniper clinician will review your options — including switching back to Mounjaro — at no extra cost.

‍

‍